NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX ... Syndax and Incyte's Niktimvo (chronic graft-versus-host disease) and Ascendis' Yorvipath (hypoparathyroidism).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback